Blood Pressure Lowering Treatment Trialists' Collaboration (BPLTTC)
The BPLTTC was conceived and initiated in 1995 as a collaboration between the principal investigators of all the major ongoing clinical trials of blood pressure lowering agents. Although previous cycles of BPLTTC have clarified the benefits and risks of blood pressure lowering, significant uncertainties of the benefits and risks of blood pressure lowering remain. A new cycle of the BPTTC aims to substantially extend the current collaboration to include up to a half a million individual participant data with all available baseline and outcome data in an effort to reduce the remaining uncertainties about the safety and efficacy of blood pressure lowering.
This new cycle of the collaboration is coordinated by the George Institute for Global Health in Oxford. Its work is governed by a Steering Committee which consists of the Director of BPLTTC, Kazem Rahimi, as well as select Principal Investigators of the largest trials included in BPLTTC. The Steering Committee is responsible for the general oversight of BPLTTC, providing scientific leadership regarding all aspects of the proposal development, analysis, interpretation and reporting.
BPLTTC was initially supported by grants from the pharmaceutical industry, including Astra Hassle AB, Bayer AG, British Heart Foundation, Bristol-Myers Squibb Company, Glaxo Wellcome, Hoechst Marion Roussel, Knoll AG, Merck and Company, Pfizer Inc., Searle, and Institut de Recherches Internationales Servier. However, since 2005, BPLTTC has not been funded by the pharmaceutical industry and has only been supported by peer reviewed sources, specifically, the National Health and Medical Research Council of Australia.